ERBB2 and breast cancer: DNA methylation at cg10816169 [RP11-867G23.13] was also found to be associated with the subtypes of breast cancer (P < 0.05), the incidence risk of HER2-Enriched-like breast cancer increased by 22% (OR 1.22, 95% CI 1.03, 1.44) and the incidence risk of triple-negative breast cancer increased by 9% (OR 1.09, 95% CI 1.01, 1.18) in the meta-analysis of BCAC and CIMBA per SD change in blood DNA methylation.